Company news
Outlook Therapeutics, Inc. news in 2022
Outlook Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update
December 28, 2022
Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 22, 2022
Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD
December 21, 2022
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
September 26, 2022
Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD
August 14, 2022
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
August 9, 2022
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note
July 4, 2022
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010
June 13, 2022
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
May 30, 2022
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update
May 12, 2022
Outlook Therapeutics to Participate in Retina World Congress 2022
May 9, 2022
Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD
March 30, 2022
Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access
March 2, 2022
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update
February 13, 2022
Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations
February 7, 2022
Outlook Therapeutics Provides a Corporate Update and Business Outlook
January 24, 2022